Pharmacy-Driven Dexmedetomidine Stewardship and Appropriate Use Guidelines in a Community Hospital Setting

Area of Science:

• Pharmacology
• Intensive Care Medicine
• Health Economics

Background:

• Dexmedetomidine is a common ICU sedative, favored for not suppressing respiratory drive and potentially reducing delirium.
• Concerns regarding dexmedetomidine therapy costs and optimal duration have prompted investigations into its appropriate use.

Purpose of the Study:

• To evaluate the effectiveness and cost-saving benefits of pharmacy-led dexmedetomidine appropriate use guidelines.
• To assess the impact of these guidelines on mechanically ventilated patients in the ICU.

Main Methods:

• A retrospective cohort study compared adult patients receiving dexmedetomidine for mechanical ventilation before and after guideline implementation.
• Patients were categorized into pre-enactment (PRE) and post-enactment (POST) groups.

Main Results:

• The POST group showed significantly shorter mechanical ventilation duration (6.2 vs 11.1 days) and lower reintubation rates (18% vs 36%).
• Dexmedetomidine vial usage and infusion days were substantially reduced in the POST group, leading to significant cost savings ($374,456.15).
• No significant differences were observed in ICU length of stay or mortality between the groups.

Conclusions:

• Pharmacy-driven appropriate use guidelines effectively decreased dexmedetomidine utilization and generated substantial cost savings.
• These guidelines improved clinical outcomes, such as reduced ventilation duration and reintubation rates, without compromising patient safety or increasing mortality.